EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

[Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?

D Moreno-Ramírez, A Fernández-Orland, L Ferrándiz

Actas Dermo-Sifiliográficas · 2024

DOI: 10.1016/j.ad.2023.10.036 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Actas Dermo-Sifiliográficas, 2024. Verfasst von D Moreno-Ramírez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Seville, Spain. Electronic add…. Hauptthemen laut MEDLINE: Mutation, Proto-Oncogene Proteins B-raf, Immunotherapy, Molecular Targeted Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic treatment with immunotherapy or targeted therapy can significantly improve survival in patients with advanced (metastatic or high-risk) melanoma. Fifty percent of patients with melanoma have a BRAF mutation. Decisions on optimal sequencing of systemic treatments should take into account drug- and tumor-related factors and patient characteristics. Although the combination of ipilimumab and nivolumab is associated with the best survival outcomes, it is associated with significant toxicity. Targeted therapy may be a more favorable option in certain clinical situations. We review the literature on immunotherapy and targeted therapy in melanoma and present an algorithm for guiding decision-making on their use as first-line systemic treatments for advanced BRAF-mutated melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationProto-Oncogene Proteins B-rafImmunotherapyMolecular Targeted TherapyMelanomaHumansNivolumabSkin Neoplasms

Stichwörter der Autor:innen

Adjuvant treatmentAnti-CTLA4Anti-PD1BRAF inhibitorsBRAF-MEK inhibitorsCTLA4 inhibitorsImmunotherapyInhibidores de BRAFInhibidores de BRAF-MEKInmunoterapiaMelanomaNeoadjuvant therapyPD1 inhibitorsTargeted therapyTerapias dirigidas

Substanzen

Proto-Oncogene Proteins B-rafNivolumabBRAF protein, human

Autor:innen und Institutionen

  • Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Seville, Spain. Electronic address: dmoreno@e.derma-org.
  • Unidad de Melanoma, Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Virgen Macarena, Seville, Spain.

Zitieren

APA

Moreno-Ramírez, D., Fernández-Orland, A., & Ferrándiz, L. (2024). [Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2023.10.036

Vancouver

Moreno-Ramírez D, Fernández-Orland A, Ferrándiz L. [Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?. Actas Dermo-Sifiliográficas. 2024. doi:10.1016/j.ad.2023.10.036

BibTeX
@article{MorenoRamrez2024,
  author = {Moreno-Ramírez, D and Fernández-Orland, A and Ferrándiz, L},
  title = {[Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2024},
  doi = {10.1016/j.ad.2023.10.036}
}
Kostenlos starten →